FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula (I): H-Tyr-D-Ala-Gly-Phe-Leu-Arg-Arg-Z, where Z is -NR1R2, where R1 and R2 are the same or different and represent hydrogen or lower an alkyl chain containing up to 4 carbon atoms, or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions based on it for use in the treatment of an HMGB1-dependent inflammatory or autoimmune disease.
EFFECT: improvement of formula compound.
7 cl, 5 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF HEXAPEPTIDE TO REDUCE LEVELS OF EXTRACELLULAR HMGB1 PROTEIN IN INFLAMMATORY DISEASES | 2021 |
|
RU2813878C2 |
| PRODRUG COMPOSITIONS WITH HIGH DEGREE OF PENETRATION BASED ON PEPTIDES AND RELATED COMPOUNDS | 2010 |
|
RU2627065C2 |
| SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION IN THE FORM OF A SUPPOSITORY CONTAINING HEXAPEPTIDE | 2020 |
|
RU2737800C1 |
| PHARMACEUTICAL COMPOSITIONS BASED ON SHK AND METHODS FOR THEIR PRODUCTION AND USE | 2012 |
|
RU2637085C2 |
| HIGH-PENETRATION PRODRUG COMPOSITIONS BASED ON PEPTIDES AND PEPTIDE-RELATED COMPOUNDS | 2010 |
|
RU2767051C2 |
| KV1_3 BLOCKERS | 2020 |
|
RU2825633C1 |
| HYDANTOIN MODIFIED MELANOCORTIN RECEPTOR LIGANDS | 2008 |
|
RU2450017C2 |
| MELANOCORTIN RECEPTOR LIGANDS | 2006 |
|
RU2380372C2 |
| SPECIFIC ACTIVATOR AKT3 AND ITS USE | 2018 |
|
RU2815372C2 |
| AGONISTS AND ANTAGONISTS OF HYBRID IL-1 RECEPTOR OF I TYPE | 2011 |
|
RU2754957C2 |
